SWX:NOVNPharmaceuticals
A Look at Novartis (SWX:NOVN) Valuation Following Strong Earnings and Major Ianalumab Trial Results
Novartis (SWX:NOVN) delivered a one-two punch this week by reporting stronger earnings and unveiling new data from its Phase III ianalumab studies in Sjogren's disease at a top rheumatology conference. Both updates are attracting investor attention.
See our latest analysis for Novartis.
After a steady climb most of the year, Novartis shares are showing renewed momentum, with a 16.92% year-to-date share price return and a 1.84% bump following this week’s headline-grabbing earnings and...